Brokerages Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $9.00

2seventy bio, Inc. (NASDAQ:TSVT) has been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $9.00.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 2seventy bio in a research report on Saturday, January 18th.

Institutional Trading of 2seventy bio

Institutional investors have recently added to or reduced their stakes in the business. Erste Asset Management GmbH bought a new position in shares of 2seventy bio during the 3rd quarter valued at $25,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of 2seventy bio in the fourth quarter worth about $32,000. SkyView Investment Advisors LLC boosted its stake in shares of 2seventy bio by 25.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after acquiring an additional 2,500 shares in the last quarter. Readystate Asset Management LP acquired a new position in shares of 2seventy bio during the 3rd quarter valued at about $53,000. Finally, GSA Capital Partners LLP bought a new position in shares of 2seventy bio in the 3rd quarter valued at approximately $64,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

2seventy bio Stock Up 3.6 %

TSVT opened at $2.60 on Friday. The firm has a market capitalization of $134.13 million, a P/E ratio of -1.40 and a beta of 1.76. The stock has a fifty day moving average of $3.12 and a 200-day moving average of $4.10. 2seventy bio has a 12-month low of $2.35 and a 12-month high of $6.40.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.